| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 28, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...
-
Dec 10, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole...
-
Nov 1, 2007-- First quarter revenue increased $43 million, or 12 percent, to $383 million
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2008 first quarter that ended September 29, 2007. Perrigo Company (in thousands, except per share...
-
Nov 1, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Dexcel Pharma Technologies, Ltd. ("Dexcel"), Perrigo's partner for store brand OTC 20mg Omeprazole delayed release tablet, has...
-
Oct 31, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors appointed President and Chief Executive Officer, Joseph C. Papa, to be Chairman of its Board of Directors....
-
Oct 30, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on December 18, 2007 to shareholders of record on...
-
Oct 19, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2008 on Thursday, November 1, 2007 at approximately 8:00 a.m. (ET)....
-
Sep 27, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it had filed an Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg, a generic version of...
-
Sep 19, 2007
The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Topical Solution,...
-
Sep 14, 2007
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that President and CEO, Joseph C. Papa and the Perrigo management team will provide a review of the Company business for the financial...